Neuland Laboratories Limited (NSE:NEULANDLAB)
India · Delayed Price · Currency is INR | Market Cap | 211.11B +25.8% |
| Revenue (ttm) | 20.53B +39.0% |
| Net Income | 3.64B +39.9% |
| EPS | 283.71 +39.9% |
| Shares Out | n/a |
| PE Ratio | 58.00 |
| Forward PE | 48.16 |
| Dividend | 12.00 (0.07%) |
| Ex-Dividend Date | Jul 18, 2025 |
| Volume | 432,634 |
| Average Volume | 74,724 |
| Open | 18,305 |
| Previous Close | 17,003 |
| Day's Range | 16,317 - 18,305 |
| 52-Week Range | 10,578 - 19,747 |
| Beta | -0.32 |
| RSI | 61.29 |
| Earnings Date | May 12, 2026 |
About Neuland Laboratories
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. [Read more]
Financial Performance
In fiscal year 2026, Neuland Laboratories's revenue was 20.53 billion, an increase of 39.02% compared to the previous year's 14.77 billion. Earnings were 3.64 billion, an increase of 39.94%.
Financial StatementsNews
Neuland Laboratories announces Rs 34 per share dividend and appoints new director
Neuland Laboratories has reported several key decisions following its recent board meeting. The company has approved a final dividend of ₹34 per equity share, representing a 340% return on a…
Neuland Laboratories Transcript: Q4 25/26
Q4 and FY 2026 saw record revenue and profit growth, driven by CMS segment performance and favorable exchange rates. Peptide business is a strategic focus, with a new facility on track and strong project pipeline. Management expects continued lumpy quarters but robust long-term growth.
Neuland Laboratories announces Rs 34 per share final dividend and capacity expansion
Neuland Laboratories has declared a final dividend of ₹34 per share for the financial year 2025-26, representing a 340% payout on the face value of ₹10 per share. The dividend…
Neuland Laboratories reports Rs 2053.1 crore total income for FY26
Neuland Laboratories Limited (NSE: NEULANDLAB), a leading pharmaceutical manufacturer, has announced its financial results for the fiscal year ending March 31, 2026. The company reported a total incom...
Neuland Laboratories reports Rs 2053.1 crore total income for Q4 FY26
Neuland Laboratories Limited has announced its financial results for the fourth quarter and the fiscal year ending March 31, 2026, reporting a total income of ₹2053.1 crore. The pharmaceutical company...
Neuland Laboratories Q4 Results: Net profit jumps 664% YoY to Rs 212.67 crore, revenue surges 136%
Neuland Laboratories reported a blockbuster performance for the fourth quarter ended March 2026, with sharp growth in revenue and profitability on a year-on-year basis. The company posted consolidated...
Neuland Laboratories appoints Saharsh Davuluri as CEO & MD to spearhead CDMO expansion
Neuland Laboratories has announced a significant leadership change with Saharsh Davuluri taking over as the Chief Executive Officer and Managing Director. This transition marks a new chapter for the c...
Pharma sector stocks today, Feb 17: Akums Drugs jumps 5%, Indegene up 4.29%, Neuland Labs surge 4.03%
The pharmaceutical sector stocks in India showed mixed performance on February 17, 2026, during early morning trading hours. Data is...
Neuland Laboratories Ltd (BOM:524558) Q3 2026 Earnings Call Highlights: Navigating Growth ...
Neuland Laboratories Ltd (BOM:524558) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst Margin Pressures
Q3 2026 Neuland Laboratories Ltd Earnings Call Transcript
Q3 2026 Neuland Laboratories Ltd Earnings Call Transcript
Neuland Laboratories Transcript: Q3 25/26
Q3 FY26 revenue grew 11.4% year-over-year, driven by CMS projects, though gross margin declined due to product mix and absence of high-margin products. Capacity expansions and new CMS molecules are expected to drive growth, with a strong pipeline and investments in peptides positioning the business for long-term success.
Neuland Labs shares jump over 7% after stellar Q2 results: Net profit surges nearly 3x YoY
Neuland Laboratories Ltd saw its shares rally more than 7% in early trade on Monday after the company delivered a...
Neuland Labs share: Nuvama maintains buy, sees 24.5% upside after strong Q2 beat and robust CMS growth
Nuvama Institutional Equities has maintained its buy call on Neuland Laboratories Ltd and raised the target price to ₹22,130 per...
[Brokerage calls] Stocks to watch today, Nov 10, 2025: Trent, Nykaa, Bajaj Auto, Hindalco, Chola Investment, Lupin, PFC, NCC, Divi’s Labs and Neuland Labs in focus
Asian markets began the week on a steady note, with a flurry of brokerage actions setting the tone for key...
Q2 2026 Neuland Laboratories Ltd Earnings Call Transcript
Q2 2026 Neuland Laboratories Ltd Earnings Call Transcript
Neuland Laboratories Transcript: Q2 25/26
Q2 FY2026 saw a 63.7% revenue surge to INR 516 crore, led by CMS/CDMO growth and improved margins. Strong customer engagement, new capacity, and ongoing investments support a positive outlook, though risks from market volatility and uneven business remain.
Neuland Labs shares surge over 2% as exports jump 433% YoY in August
Shares of Neuland Laboratories Ltd surged more than 2% on Tuesday, trading at ₹16,041, after the company reported a stellar rise in export performance for August 2025. The pharma firm posted exports w...
Neuland Laboratories shares fall nearly 4% after weak Q1 results
Shares of Neuland Laboratories fell nearly 4% on Friday, August 1, closing at ₹12,761, after the company reported disappointing Q1FY26 results. The pharmaceutical firm posted a net profit of ₹13.90 cr...
Neuland Laboratories Transcript: Q1 25/26
Q1 FY26 saw a 32.4% revenue decline and margin compression due to uneven order flow, but management remains optimistic about strong FY26 growth as new capacities and commercial molecules ramp up. Peptide investments and CMS pipeline expansion are on track.
Over 40 stocks trade ex-dividend today; Kotak Mahindra Bank, Bharti Airtel, Cummins, Dabur, Intellect Design, Birlasoft, Neuland Labs in focus
A large number of companies are trading ex-dividend today, July 18, ahead of their scheduled record dates for dividend payouts. Some notable names include Bharti Airtel, Cummins India, Dabur, Birlasof...
Neuland Laboratories share price drops 5% as Q4 EBITDA falls 52.3% YoY to Rs 51 crore
Neuland Laboratories witnessed a sharp decline in its share price, falling nearly 5% after the company reported a disappointing set of numbers for the fourth quarter. As of 9:30 AM, the shares were tr...
Neuland Laboratories Transcript: Q4 24/25
Q4 and FY25 saw revenue and profit declines due to product mix and lifecycle effects, but strong free cash flow and reduced net debt position the company for growth. New capacity and product launches are expected to drive a rebound in FY26, with CMS and GDS segments both set to grow.
Neuland Laboratories receives one FDA observation following inspection of Unit 2 facility in Telangana
Neuland Laboratories Ltd. has announced that the United States Food and Drug Administration (US FDA) recently conducted an inspection of its Unit 2 manufacturing facility located in Pashamylaram villa...
Neuland Laboratories Transcript: Q3 24/25
Q3 saw modest revenue growth and a strong profit after tax due to an exceptional gain, though margins declined year-over-year. FY25 is expected to be flat, with growth resuming in FY26, supported by capacity expansion and a robust order pipeline. Major investments in peptides and improved ESG ratings highlight strategic progress.
Neuland Laboratories shares drop 6% as Q3 EBITDA falls 29% YoY
Neuland Laboratories saw its shares drop 6% after reporting mixed financial results for the third quarter. As of 9:23 AM, the shares were trading 6.04% lower at Rs 13,786.90. While the company’s reven...